Media resources

Media

Access media assets, breaking news, press releases, and scientific publications

Explore this page for media resources, including a press kit, current news, and press releases. To sign up for breaking news alerts, register here. For media inquiries, please contact us at Media@Akebia.com.

Media kit

Includes logos, leadership photography and bios

Download all media kit assets (ZIP file, 5.5 MB)


Akebia logo

ZIP (285KB)

Akebia logo (white/knockout)

ZIP (617KB)


John Butler (President and CEO) photos and biography

Portrait

Hi-res JPG (402KB)

Full-length

Hi-res JPG (1MB)

Candid

JPG (72KB)

Biography

PDF Biography (145KB)


Recent press releases

Monday, February 13, 2017
Akebia Licenses Portfolio of Novel HIF Compounds from Johnson & Johnson Innovation

Friday, February 3, 2017
Akebia to Present at the 19th BIO CEO & Investor Conference

Tuesday, December 20, 2016
Akebia and Otsuka Pharmaceutical Announce Collaboration to Develop and Commercialize Vadadustat in the U.S.

View all press releases »


Featured news articles

Monday, November 3, 2014
BioCentury: Full Steam Ahead

Wednesday, June 9, 2014
Xconomy: Akebia, Trading M&A For an IPO, Follows Fast in Anemia Drug Race

Friday, March 21, 2014
CNBC – Squawk on the Street: Akebia IPO Highlighted

View all news articles »


Recent publications

2015 ASN: Posters
Vadadustat Demonstrates Controlled Hemoglobin Response in a Phase 2b Study for the Treatment of Anemia in Patients with Non-Dialysis Dependent Chronic Kidney Disease

Dose Exposure Relationship of Vadadustat is Independent of the Level of Renal Function

Vadadustat, a Novel, Oral Treatment for Anemia of CKD, Maintains Stable Hemoglobin Levels in Dialysis Patients Converting from Erythropoiesis-Stimulating Agents

2014 ASN: Posters
Phase 2 Study of AKB-6548, a novel hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI) in patients with end stage renal disease (ESRD) undergoing hemodialysis (HD)

Hemodialysis has minimal impact on the pharmacokinetics of AKB-6548, a once-daily oral inhibitor of hypoxia-inducible factor prolyl-hydroxylases (HIF-PHs) for the treatment of anemia related to chronic kidney disease (CKD)

View all publications »